A safety-modified SV40 Tag developed for human cancer immunotherapy

Drug Design, Development and Therapy

Volumn , Issue 2, 2008, Pages 17-24

  Tseng Rogenski, Stephanie S ^a   Arredouani, Mohamed S ^b   Escara Wilke, June F ^a   Neeley, Yilin C ^a   Imperiale, Michael J ^a   Sanda, Martin G ^a,b  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Cancer immunotherapy; Modified SV 40 T antigen; Recombinant vaccinia

Indexed keywords

EPITOPE; HLA A2 ANTIGEN; ONCOPROTEIN; RECOMBINANT VACCINE; VIRUS T ANTIGEN; VIRUS VACCINE;

ANIMAL CELL; ARTICLE; CANCER IMMUNOTHERAPY; CARCINOGENICITY; CONTROLLED STUDY; DNA SEQUENCE; DRUG SAFETY; EMBRYO; ENZYME LINKED IMMUNOSPOT ASSAY; GENETIC TRANSFECTION; IMMUNOPRECIPITATION; MOUSE; NONHUMAN; PROTEIN DEGRADATION; SCREENING TEST; SEQUENCE TAGGED SITE; SIMIAN VIRUS 40; WESTERN BLOTTING;

EID: 77952941257     PISSN: None     EISSN: 11778881     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Ahuja D, Saenz-Robles MT, Pipas JM. 2005. SV40 large T antigen targets multiple cellular pathways to elicit cellular transformation. Oncogene, 24:7729-7745
2. Bender MA, Christensen J, Brockman WW. 1983. Characterization of a T-antigen-negative revertant isolated from a mouse cell line which undergoes rearrangement of integrated simian virus 40 DNA. J Virol, 47:115-124
3. Brooks SE, Adachi M, Hoffman LM, et al. 1988. Induction of lymphomas and fibrosarcomas in nude mice after implantation of simian virus 40-transformed human meningioma. Lab Invest, 58:518-523
4. Butel JS, Lednicky JA. 1999. Cell and molecular biology of simian virus 40: implications for human infections and disease. J Natl Cancer Inst, 91:119-134
5. Carbone M, Rizzo P, Pass HI. 1997. Simian virus 40, poliovaccines and human tumors: a review of recent developments. Oncogene, 15:1877-1888
6. Deppert W, Haug M, Steinmayer T. 1987. Modulation of p53 protein expression during cellular transformation with simian virus 40. Mol Cell Biol, 7:4453-4463
7. Garcea RL, Imperiale MJ. 2003. Simian virus 40 infection of humans. J Virol, 77:5039-5045
8. Inaba K, Inaba M, Romani N, et al. 1992. Generation of large numbers of dendritic cells from mouse bone marrow cultures supplemented with granulocyte/macrophage colony-stimulating factor. J Exp Med, 176:1693-1702
9. Jasani B, Cristaudo A, Emri SA, et al. 2001. Association of SV40 with human tumours. Semin Cancer Biol, 11:49-61.
10. Klein G, Powers A, Croce C. 2002. Association of SV40 with human tumors. Oncogene, 21:1141-1149
11. Kohli M, Jorgensen TJ. 1999. The influence of SV40 immortalization of human fibroblasts on p53-dependent radiation responses. Biochem Biophys Res Commun, 257:168-176
12. Mylin LM, Bonneau RH, Lippolis JD, et al. 1995. Hierarchy among multiple H-2b-restricted cytotoxic T-lymphocyte epitopes within simian virus 40 T antigen. J Virol, 69:6665-6677
13. Phelps AL, Gates AJ, Hillier M, et al. 2007. Comparative efficacy of modified vaccinia Ankara (MVA) as a potential replacement smallpox vaccine. Vaccine, 25:34-42. (Pubitemid 44855248)
14. Reddel RR, Salghetti SE, Willey JC, et al. 1993. Development of tumorigenicity in simian virus 40-immortalized human bronchial epithelial cell lines. Cancer Res, 53:985-991
15. Schell TD, Lippolis JD, Tevethia SS. 2001. Cytotoxic T lymphocytes from HLA-A2.1 transgenic mice de. ne a potential human epitope from simian virus 40 large T antigen. Cancer Res, 61:873-879
16. Shah KV. 2000. Does SV40 infection contribute to the development of human cancers? Rev Med Virol, 10:31-43.
17. Shen Y, Nemunaitis J. 2005. Fighting cancer with vaccinia virus: teaching new tricks to an old dog. Mol Ther, 11:180-195 (Pubitemid 40163961)
18. Song GY, Gibson G, Haq W, et al. 2007. An MVA vaccine overcomes tolerance to human p53 in mice and humans. Cancer Immunol Immunother, 56:1193-1205
19. Tanaka Y, Tevethia MJ, Kalderon D, et al. 1988. Clustering of antigenic sites recognized by cytotoxic T lymphocyte clones in the amino terminal half of SV40 T antigen. Virology, 162:427-436 (Pubitemid 18068926)
20. Vilchez RA, Butel JS. 2003a. Simian virus 40 and its association with human lymphomas. Curr Oncol Rep, 5:372-379 (Pubitemid 38898806)
21. Vilchez RA, Butel JS. 2003b. Simian virus 40 infection in lymphoproliferative disorders. Lancet, 361:1565; author reply 1565-1566
22. Xie YC, Hwang C, Overwijk W, et al. 1999. Induction of tumor antigen-specific immunity in vivo by a novel vaccinia vector encoding safety-modified simian virus 40 T antigen. J Natl Cancer Inst, 91:169-175 (Pubitemid 29042695)